Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Hodgkin's Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT05967416
What this trial is testing

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Refractory Non-Hodgkin LymphomaRelapsed Non-Hodgkin Lymphoma
SIRPant Immunotherapeutics, Inc. 24
Testing effectiveness (Phase 2)Study completedNCT01466881
What this trial is testing

Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

Who this might be right for
Adult Nasal Type Extranodal NK/T-Cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-Cell Lymphoma+4 more
National Cancer Institute (NCI) 42
Testing effectiveness (Phase 2)Ended earlyNCT03578198
What this trial is testing

Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)

Who this might be right for
CD20-positive Non-Hodgkin Lymphoma
Seoul National University Hospital 12
Testing effectiveness (Phase 2)Study completedNCT00848926
What this trial is testing

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

Who this might be right for
Disease, Hodgkin
Seagen Inc. 102
Testing effectiveness (Phase 2)Study completedNCT00867529
What this trial is testing

Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma

Who this might be right for
B-cell Adult Acute Lymphoblastic LeukemiaB-cell Childhood Acute Lymphoblastic LeukemiaB-cell Chronic Lymphocytic Leukemia+35 more
Fred Hutchinson Cancer Center 63
Early research (Phase 1)Study completedNCT02595866
What this trial is testing

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Who this might be right for
AIDS-Related Non-Hodgkin LymphomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+16 more
National Cancer Institute (NCI) 58
Large-scale testing (Phase 3)Study completedNCT03575351
What this trial is testing

Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

Who this might be right for
Lymphoma, Non-Hodgkin
Celgene 184
Early research (Phase 1)Study completedNCT00003294
What this trial is testing

Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer

Who this might be right for
LeukemiaLymphomaUnspecified Adult Solid Tumor, Protocol Specific
Roswell Park Cancer Institute 24
Testing effectiveness (Phase 2)Study completedNCT01453205
What this trial is testing

A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-Cell Lymphoma
MedImmune LLC 187
Testing effectiveness (Phase 2)Study completedNCT00179673
What this trial is testing

Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkins Lymphoma
Celgene 43
Early research (Phase 1)Ended earlyNCT03465540
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Who this might be right for
Multiple MyelomaAcute Myeloid LeukemiaNon-Hodgkins Lymphoma+4 more
Amgen 24
Testing effectiveness (Phase 2)Ended earlyNCT04161118
What this trial is testing

TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Who this might be right for
Non Hodgkin Lymphoma
University of Cologne 3
Testing effectiveness (Phase 2)Ended earlyNCT06088654
What this trial is testing

Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Non Hodgkin Lymphoma
Innate Pharma 23
Early research (Phase 1)WithdrawnNCT01789723
What this trial is testing

Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn

Who this might be right for
Non Hodgkin's Lymphoma
Acrotech Biopharma Inc.
Testing effectiveness (Phase 2)Study completedNCT04318080
What this trial is testing

Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Classical Hodgkin Lymphoma
BeiGene 46
Testing effectiveness (Phase 2)Study completedNCT02207062
What this trial is testing

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

Who this might be right for
Recurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory Transformed B-Cell Non-Hodgkin Lymphoma
University of Washington 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT03155620
What this trial is testing

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin Lymphoma+42 more
National Cancer Institute (NCI) 1,377
Early research (Phase 1)Active Not RecruitingNCT01695941
What this trial is testing

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Mantle Cell LymphomaRefractory B-Cell Non-Hodgkin Lymphoma+1 more
National Cancer Institute (NCI) 24
Large-scale testing (Phase 3)Study completedNCT00799461
What this trial is testing

Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+89 more
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium 1,337
Testing effectiveness (Phase 2)Study completedNCT00276003
What this trial is testing

INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.

Who this might be right for
Non-Hodgkin's LymphomaCancer
University of New Mexico 22
Next Page